Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board, which met on November 17, 2015 in New York.
Neovacs convened its Scientific Advisory Board with the clear mission to identify novel cytokine/growth factor targets in oncology. Neovacs` proprietary technology is based on active immunotherapy, which stimulates a patients immune system to produce polyclonal antibodies, neutralizing pathogenic proteins.
As a result of their work, the Scientific Advisory Board recommended Neovacs to focus on the preclinical development of specific Kinoid`s targeting the Neutralization of tumoral growth factors including VEGF-A in different types of cancer, in particular colorectal cancer and ovarian cancers.